343 related articles for article (PubMed ID: 28119255)
1. Limitations of current liver transplant immunosuppressive regimens: renal considerations.
Zhang W; Fung J
Hepatobiliary Pancreat Dis Int; 2017 Feb; 16(1):27-32. PubMed ID: 28119255
[TBL] [Abstract][Full Text] [Related]
2. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
3. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
Flechner SM; Kobashigawa J; Klintmalm G
Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
[TBL] [Abstract][Full Text] [Related]
4. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
[TBL] [Abstract][Full Text] [Related]
5. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
[TBL] [Abstract][Full Text] [Related]
6. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study.
Karie-Guigues S; Janus N; Saliba F; Dumortier J; Duvoux C; Calmus Y; Lorho R; Deray G; Launay-Vacher V; Pageaux GP
Liver Transpl; 2009 Sep; 15(9):1083-91. PubMed ID: 19718632
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
[TBL] [Abstract][Full Text] [Related]
8. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppression Modification by Everolimus With Minimization of Calcineurin Inhibitors Recovers Kidney Graft Function Even in Patients With Very Late Conversion and Also With Poor Graft Function.
Nojima M; Yamada Y; Higuchi Y; Shimatani K; Kanematsu A; Yamamoto S
Transplant Proc; 2017; 49(1):41-44. PubMed ID: 28104155
[TBL] [Abstract][Full Text] [Related]
10. Arteriosclerosis in zero-time biopsy is a risk factor for tacrolimus-induced chronic nephrotoxicity.
Yagisawa T; Omoto K; Shimizu T; Ishida H; Tanabe K
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():51-7. PubMed ID: 26031587
[TBL] [Abstract][Full Text] [Related]
11. Calcineurin Inhibitor-Sparing Strategies in Renal Transplantation: Where Are We? A Comprehensive Review of the Current Evidence.
Camilleri B; Bridson JM; Halawa A
Exp Clin Transplant; 2016 Oct; 14(5):471-483. PubMed ID: 27213490
[TBL] [Abstract][Full Text] [Related]
12. Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation.
Chapman WC; Brown RS; Chavin KD; Sudan D; Koneru B; Junge G; Dong G; Patel D; Teperman L; Fung JJ
Transplantation; 2017 Feb; 101(2):341-349. PubMed ID: 28121741
[TBL] [Abstract][Full Text] [Related]
13. Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis.
Lin M; Mittal S; Sahebjam F; Rana A; Sood GK
Clin Transplant; 2017 Feb; 31(2):. PubMed ID: 27862340
[TBL] [Abstract][Full Text] [Related]
14. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
Nankivell BJ; PʼNg CH; OʼConnell PJ; Chapman JR
Transplantation; 2016 Aug; 100(8):1723-31. PubMed ID: 27306529
[TBL] [Abstract][Full Text] [Related]
15. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
[TBL] [Abstract][Full Text] [Related]
16. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.
Burkhalter F; Oettl T; Descoeudres B; Bachmann A; Guerke L; Mihatsch MJ; Dickenmann M; Steiger J
Transplant Proc; 2012 Dec; 44(10):2961-5. PubMed ID: 23195006
[TBL] [Abstract][Full Text] [Related]
17. Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy.
Helmschrott M; Rivinius R; Bruckner T; Katus HA; Doesch AO
Drug Des Devel Ther; 2017; 11():1673-1680. PubMed ID: 28652705
[TBL] [Abstract][Full Text] [Related]
18. Conversion to everolimus in liver transplant patients with renal dysfunction.
Pérez T; Segovia R; Castro L; Roblero JP; Estela R
Transplant Proc; 2011; 43(6):2307-10. PubMed ID: 21839260
[TBL] [Abstract][Full Text] [Related]
19. Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation: A Meta-Analysis of Randomized Controlled Trials.
Glover TE; Watson CJ; Gibbs P; Bradley JA; Ntzani EE; Kosmoliaptsis V
Transplantation; 2016 Mar; 100(3):621-9. PubMed ID: 26636736
[TBL] [Abstract][Full Text] [Related]
20. Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis.
Su L; Tam N; Deng R; Chen P; Li H; Wu L
Int Urol Nephrol; 2014 Oct; 46(10):2035-44. PubMed ID: 25027805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
